Eleven has a pipeline of novel therapies, called Targeted Protein Therapeutics (TPTs), based upon antibody fragments genetically fused to cytotoxic proteins that are innovative anti-cancer treatments.
Our first generation of TPTs are locoregional therapies for treatment of cancer. These locoregional TPTs are believed directly kill tumor cells that they are targeted to as well as initiate patient anti-tumor immune responses, potentially making them attractive for both single agent and combination treatment strategies with immune-oncology agents such as checkpoint inhibitors.
The most advanced drug candidates in our pipeline are locoregional TPTs:
- Vicinium™, a fully biologic engineered protein designed for targeted tumor local therapy to EpCAM positive tumor cells, is in an active Phase 3 clinical trial in the U.S. and Canada for the treatment of high-grade non-muscle invasive bladder cancer (NMIBC), with topline data expected in the first half of 2018.
- Proxinium™ is being developed for late stage squamous cell carcinoma of the head and neck. A Phase 2 clinical trial evaluating Proxinium as a single agent versus Proxinium in combination with a checkpoint inhibitor is planned for the first half of 2017.
Eleven has earlier pipeline candidates of next generation TPTs that are designed and optimized for systemic administration to treat a broader spectrum of cancer types.